Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Vaccine|March 21, 2026
Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trialAdora Rooyakkers, Lingyun Ye, Pedro E Cahn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 17, 2018
A Randomized Controlled Trial of the Safety and Immunogenicity of Tetanus, Diphtheria, and Acellular Pertussis Vaccine Immunization During Pregnancy and Subsequent Infant Immune ResponseScott A Halperin, Joanne M Langley, Lingyun Ye, et al.
Lancet (London, England)|December 26, 2021
Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trialScott A Halperin, Lingyun Ye, Donna MacKinnon-Cameron, et al.
Medrxiv : the Preprint Server for Health Sciences|June 29, 2026
A controlled human infection model for symptomatic pertussis in North America using the pertactin-producing clinical isolate D420May S ElSherif, Kara L Redden, Joanne M Langley, et al.
Translational Lung Cancer Research|May 19, 2020
Challenges and countermeasures of thoracic oncology in the epidemic of COVID-19Haoyue Guo, Xiaoxia Chen, Chunxia Su, et al.
Vaccine|September 16, 2025
Safety and immunogenicity of COVAC-2, a Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in healthy adults; a randomized controlled first-in-human dose-escalation trialGlenn Hamonic, Elodie Pastural, Supriya Arora, et al.
BMJ Open Respiratory Research|March 20, 2020
Age-stratified burden of pneumococcal community acquired pneumonia in hospitalised Canadian adults from 2010 to 2015Jason LeBlanc, May ElSherif, Lingyun Ye, et al.
Vaccine|July 27, 2019
Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN)Jason J LeBlanc, May ElSherif, Lingyun Ye, et al.
Lung Cancer (Amsterdam, Netherlands)|November 17, 2024
Evaluating efficacy and safety of a novel registration-free CT-guided needle biopsy navigation system (RC 120): A multicenter, prospective clinical trialLei Wang, Biao Song, Zheng Zhang, et al.
Vaccine|May 31, 2017
Burden of vaccine-preventable pneumococcal disease in hospitalized adults: A Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) network studyJason J LeBlanc, May ElSherif, Lingyun Ye, et al.
Pageof 8